University of Oxford Confidence in Concept Scheme – Round 6
Lead Research Organisation:
University of Oxford
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
People |
ORCID iD |
Publications
Bhusal RP
(2020)
Evasins: Tick Salivary Proteins that Inhibit Mammalian Chemokines.
in Trends in biochemical sciences
Cutts A
(2019)
A method for noninvasive prenatal diagnosis of monogenic autosomal recessive disorders.
in Blood
Dar G
(2021)
Author Correction: GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain
in Nature Communications
Dar GH
(2021)
GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain.
in Nature communications
Donnison T
(2022)
A pan-genotype hepatitis C virus viral vector vaccine generates T cells and neutralizing antibodies in mice.
in Hepatology (Baltimore, Md.)
Lin D
(2018)
MetClo: methylase-assisted hierarchical DNA assembly using a single type IIS restriction enzyme.
in Nucleic acids research
Lin D
(2020)
Hierarchical Modular DNA Assembly Using MetClo.
in Methods in molecular biology (Clifton, N.J.)
Lin D
(2018)
MetClo: methylase-assisted hierarchical DNA assembly using a single type IIS restriction enzyme.
in Nucleic acids research
Nasser A
(2021)
Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania.
in Blood advances
| Description | American Thoracic Society technical statement on pre-school multi-breath washout testing - Grant Ritchie Project |
| Geographic Reach | North America |
| Policy Influence Type | Citation in other policy documents |
| URL | https://www.ncbi.nlm.nih.gov/pubmed/29493315 |
| Description | CML diagnostic service in Muhimbili National Hospital funded by Tanzanian Government and led to change in practice - Anna Schuh Project |
| Geographic Reach | Africa |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | CML diagnostic service in Muhimbili National Hospital (Dar Es Salaam) is now funded by the Tanzanian Government and had led to change in practice as it allows free access to highly effective drugs |
| Description | 3 year research agreement to develop Universal Influenza Vaccine and surrounding research portfolio - Sunetra Gupta Project |
| Amount | £420,000 (GBP) |
| Organisation | Blue Water Vaccines Inc. |
| Sector | Private |
| Country | United States |
| Start | |
| Description | A pipeline directly from synthetic linear DNA |
| Amount | £85,261 (GBP) |
| Organisation | Medical and Life Sciences Translational Fund |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Acute Leukaemia Diagnosis: Transfer sequencing technology for leukaemia diagnosis |
| Amount | £260,000 (GBP) |
| Organisation | Business for Social Responsibility |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 01/2021 |
| End | 01/2023 |
| Description | AfOx Visiting Fellowship for President of the Tanzanian Society of Human Genetics - Anna Schuh Project |
| Amount | £6,000 (GBP) |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Brain Delivery Of RNA Based Therapy Using Antibody And Bispecific Antibody-RNA Conjugates (Arcs) - Suzan Hammond Project |
| Amount | £918,141 (GBP) |
| Organisation | RT Ventures |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | Global Haematology Scholarship: Visiting fellowship to learn Nanopore technology and attend Early Phase Clinical Trial Unit and haematology service in Oxford - Anna Schuh Project |
| Amount | £6,000 (GBP) |
| Organisation | British Society for Haematology |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Improving diagnosis of CLL - Anna Schuh. To pilot Global Health Research Initiative benefitting patients with CLL |
| Amount | £125,000 (GBP) |
| Organisation | National Institutes of Health (NIH) |
| Department | National Cancer Institute (NCI) |
| Sector | Public |
| Country | United States |
| Start | 01/2021 |
| End | 01/2023 |
| Description | MLSTF Enhanced Internal - Anna Schuh Plus In-kind support from Nanopore |
| Amount | £50,700 (GBP) |
| Organisation | Oxford Nanopore Technologies |
| Sector | Private |
| Country | United Kingdom |
| Start | 08/2019 |
| End | 08/2020 |
| Description | MLSTF: "To expand test repertoire to Nanopore technology and leukaemia indications" - Anna Schuh Project |
| Amount | £37,400 (GBP) |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Novel antibody-oligonucleotide drug conjugates target the CNS to treat neuromuscular disease |
| Amount | £225,000 (GBP) |
| Funding ID | 19GRO-PG36-0294 |
| Organisation | Muscular Dystrophy UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2020 |
| End | 12/2022 |
| Description | Phase I clinical trial in collaboration with Oxford Vaccine Group - Sunetra Gupta Project |
| Amount | £590,000 (GBP) |
| Organisation | Blue Water Vaccines Inc. |
| Sector | Private |
| Country | United States |
| Start | |
| Description | Research and Innovation for Global Health Transformation (RIGHT): "Evaluation and Transfer of mobile whole slide tissue scanners...for improved outcomes of children and young adults with EBV-driven lymphoma" - Anna Schuh Project |
| Amount | £4,300,000 (GBP) |
| Funding ID | NIHR200133 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | SIDA Tanzania: Frequency of TP53 mutation in patients with chronic lymphocytic leukemia at Muhimbili National Hospital - Anna Schuh Project |
| Amount | £10,000 (GBP) |
| Organisation | Swedish International Development Cooperation Agency |
| Sector | Public |
| Country | Global |
| Start | |
| Description | The Idealised Lung Clearance Index: tuning in to the silent years of cystic fibrosis - Grant Ritchie Project |
| Amount | £461,345 (GBP) |
| Funding ID | EP/T001186/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | The idealised LCI (i-LCI): tuning in on the 'silent years' of paediatric CF - Grant Ritchie Project |
| Amount | £98,594 (GBP) |
| Organisation | Cystic Fibrosis Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Title | Establish a pipeline for identifying highly immunogenic and potent vaccine targets - Sunetra Gupta project |
| Description | Establish a pipeline for identifying highly immunogenic and potent vaccine targets |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2019 |
| Provided To Others? | No |
| Impact | Potential for identifying other highly immunogenic and potent vaccine targets |
| Title | Produce an immunogenic virus-like particle that can be synthesised cheaply in E.coli or used in a viral vector - Sunetra Gupta Project |
| Description | Production of an immunogenic virus-like particle that can be synthesised cheaply in E.coli or used in a viral vector |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2019 |
| Provided To Others? | No |
| Impact | Identification of other vaccine targets for other pathogens. |
| Description | Acute Leukaemia Diagnostics: Illumina - Anna Schuh |
| Organisation | Illumina Inc. |
| Department | Illumina |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Expansion of our test reservoir. Building of our DNA Sequencing laboratory at MUHAS |
| Collaborator Contribution | Transfer sequencing technology for leukaemia diagnosis |
| Impact | n/a |
| Start Year | 2021 |
| Description | AstraZeneca partnership to explore the use of anti-TfR-ASOs for Huntington's Disease - Suzan Hammond project |
| Organisation | AstraZeneca |
| Department | Astra Zeneca |
| Country | United States |
| Sector | Private |
| PI Contribution | Joint application for research assistant to explore the use of anti-TfR-ASOs for Huntington's Disease |
| Collaborator Contribution | Joint application for research assistant to explore the use of anti-TfR-ASOs for Huntington's Disease |
| Impact | Joint application for post doctoral researcher will yield further research outputs |
| Start Year | 2019 |
| Description | Brain delivery of RNA based therapy using Antibody and bispecific antibody-RNA conjugates (ARCs) - Suzan Hammond |
| Organisation | RT Ventures |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The aim of this proposal is to develop monoclonal and bispecfic antibodies that can target discovery of oligonucleotide therapy to specific neuronal types in the brain and spinal cord for therapeutic delivery of RNA based therapies for neurodegenerative diseases |
| Collaborator Contribution | the venture fund group RT Ventures has provided funding for 18 months to accelerate the program into a potential spin-out. Licensing agreements are still in negotiation. |
| Impact | Not quite yet. |
| Start Year | 2020 |
| Description | Novel Antibody Oligonucleotide drug conjugates target the CNS to treat neuromuscular disease. Suzan Hammond |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Funding has been provided by Muscular Dystrophy UK. The aim of this proposal is to develop novel mAb-ASO and BsAb-ASOs for treatment of spinal muscular atrophy and create a platform of Ab selection that we can use to generate new Ab-ASO drug compounds for multiple neuromuscular diseases |
| Collaborator Contribution | Partnered up with AstraZeneca to explore the use of anti-TfR-ASOs for Huntington's Disease through an application for a postdoctoral researcher to work between AZ and myself. |
| Impact | n/a |
| Start Year | 2020 |
| Title | AN EXTRACELLULAR VESICLE |
| Description | The present invention relates to compositions for the delivery of molecules such as a peptide, a nucleic acid and/or a small molecule drug. In particular, the present invention relates to an extracellular vesicle (EV) loaded with a peptide, a nucleic acid and/or a small molecule drug, along with methods of producing said EV. |
| IP Reference | WO2021084274 |
| Protection | Patent granted |
| Year Protection Granted | 2021 |
| Licensed | No |
| Impact | Further development of IP is ongoing |
| Title | Investigation of Levetiracetam in Alzheimer's Disease (The ILiAD Trial); a proof of concept study - Arjune Sen Project |
| Description | Unique proof of concept, randomised, double blind, placebo controlled cross-over trial using Levetiracetam, a medicine used to treat epilepsy, in Alzheimer's Disease. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2020 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | Testing of licensed drug in another indication |
| URL | https://www.nhs.uk/medicines/levetiracetam/ |
| Company Name | BLUE WATER VACCINES INC. |
| Description | A company developing a universal flu vaccine based on technology developed at the University of Oxford |
| Year Established | 2019 |
| Impact | Vaccine development & clinical trials |
| Website | https://www.bluewatervaccines.com/ |
| Company Name | GYREOX LIMITED |
| Description | GyreOx is a privately-held biotechnology company, based on the Harwell Campus, Oxfordshire, UK. The Company is focussed on creating novel medicines addressing complex intra-cellular targets in a wide range of diseases. Its proprietary platform technology is based on a combination of chemistry and synthetic biology deploying a set of rationally engineered enzymes. |
| Year Established | 2019 |
| Impact | We have created a chemoenzymatic technology for macrocycle generation. The technology consists of a set of flexible engineered enzymes which can carry out modification steps on a synthetic linear substrate to generate modified macrocycles. |
| Website | https://www.gyreox.com/ |
| Company Name | Lime Biosciences Ltd |
| Description | Research and experimental development on biotechnology and DNA assembly |
| Year Established | 2019 |
| Impact | None yet |
| Description | British Neuroscience Association |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Presented research in the form of a talk. Scientific Meeting. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://meetings.bna.org.uk/bna2019/ |
| Description | International Oligonucleotides and Peptides Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Academic and Industry partner meeting for development of Oligo and Peptide technologies |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.iopc-tks.com/past-edition/ |
| Description | International workshop in CLL in Edinburgh - Anna Schuh Project |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Programme Committee co-chair for the international workshop in CLL in Edinburgh (2000 delegates); PI Anna Schuh introduced a new session on "global CLL" with invited speakers from all continents |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.iwcll2019.org/ |
| Description | Oligonucleotide Therapeutic Society 2018 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Presented work in the form of a talk. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.oligotherapeutics.org/2018-annual-meeting/ |
| Description | Oligonucleotide Therapeutic Society 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Presented new research |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.oligotherapeutics.org/2019-annual-meeting/ |
| Description | Presentation to Tanzanian Minister of Health - Anna Schuh Project |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Presentation to Tanzanian Minister of Health during the AORTIC meeting in Mozambique in 2019. Presentation has potential to influence health policy across Tanzania |
| Year(s) Of Engagement Activity | 2019 |
| Description | Talk - SMA Europe 2020 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Scientific research talk to disseminate the work generated and increase awarness. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.sma-europe.eu/our-projects/our-congresses/congress-2020/ |